These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29370526)

  • 1. Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.
    Liu Q; Zhu H; Tiruthani K; Shen L; Chen F; Gao K; Zhang X; Hou L; Wang D; Liu R; Huang L
    ACS Nano; 2018 Feb; 12(2):1250-1261. PubMed ID: 29370526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
    Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
    J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.
    Behera R; Kaur A; Webster MR; Kim S; Ndoye A; Kugel CH; Alicea GM; Wang J; Ghosh K; Cheng P; Lisanti S; Marchbank K; Dang V; Levesque M; Dummer R; Xu X; Herlyn M; Aplin AE; Roesch A; Caino C; Altieri DC; Weeraratna AT
    Clin Cancer Res; 2017 Jun; 23(12):3181-3190. PubMed ID: 28232477
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
    Mohapatra P; Prasad CP; Andersson T
    Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.
    Webster MR; Fane ME; Alicea GM; Basu S; Kossenkov AV; Marino GE; Douglass SM; Kaur A; Ecker BL; Gnanapradeepan K; Ndoye A; Kugel C; Valiga A; Palmer J; Liu Q; Xu X; Morris J; Yin X; Wu H; Xu W; Zheng C; Karakousis GC; Amaravadi RK; Mitchell TC; Almeida FV; Xiao M; Rebecca VW; Wang YJ; Schuchter LM; Herlyn M; Murphy ME; Weeraratna AT
    Mol Cell; 2020 Feb; 77(3):633-644.e5. PubMed ID: 31836388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.
    Coupe N; Guo L; Bridges E; Campo L; Espinosa O; Colling R; Marshall A; Nandakumar A; van Stiphout R; Buffa FM; Corrie PG; Middleton MR; Macaulay VM
    Cell Oncol (Dordr); 2023 Apr; 46(2):391-407. PubMed ID: 36539575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.
    Liu Q; Chen F; Hou L; Shen L; Zhang X; Wang D; Huang L
    ACS Nano; 2018 Aug; 12(8):7812-7825. PubMed ID: 30016071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.
    Liu Q; Zhu H; Liu Y; Musetti S; Huang L
    Cancer Immunol Immunother; 2018 Feb; 67(2):299-310. PubMed ID: 29094184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity.
    Douglass SM; Fane ME; Sanseviero E; Ecker BL; Kugel CH; Behera R; Kumar V; Tcyganov EN; Yin X; Liu Q; Chhabra Y; Alicea GM; Kuruvilla R; Gabrilovich DI; Weeraratna AT
    Cancer Res; 2021 Feb; 81(3):658-670. PubMed ID: 33262126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light-controlled inhibition of BRAFV600E kinase.
    Hoorens MWH; Ourailidou ME; Rodat T; van der Wouden PE; Kobauri P; Kriegs M; Peifer C; Feringa BL; Dekker FJ; Szymanski W
    Eur J Med Chem; 2019 Oct; 179():133-146. PubMed ID: 31252305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel.
    Jin H; Wan C; Zou Z; Zhao G; Zhang L; Geng Y; Chen T; Huang A; Jiang F; Feng JP; Lovell JF; Chen J; Wu G; Yang K
    ACS Nano; 2018 Apr; 12(4):3295-3310. PubMed ID: 29558107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
    Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
    Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells.
    Ramisetti SR; Pandey MK; Lee SY; Karelia D; Narayan S; Amin S; Sharma AK
    Eur J Med Chem; 2018 Jan; 143():1919-1930. PubMed ID: 29133035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
    de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
    Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.